If fasting guidelines are instead meant to minimize aspiration events without respect to residual gastric contents, then I think we need to start questioning what amount of residual gastric contents (and what type) are clinically significant.2 Oprea and colleagues published a correspondence this month addressing some of the criticisms of their article
The FDA proposed to exclude semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and liraglutide (Saxenda, Victoza), popular glucagon-like peptide-1 (GLP-1) medications, from the 503B bulk list, citing a lack of clinical need for outsourcing facilities to compound these medications from bulk drug substances
Skip aspiration for subcutaneous shots it isnt needed
Your body's potential recovery partner Injuries, inflammation, and digestive discomfort can slow you down but your body already has natural repair processes